Raised fiscal 2026 guidance reflects strong U.S. execution and One Oncology, despite higher interest expense and paused buybacks.
| Quarter | Q1 FY26 |
|---|---|
| Call date | 2026-02-04 |
| Length | 59 minutes |
| EPS | $4.08 |
| EPS consensus | $4.07 |
| Revenue | $85.9B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q3 FY26 · Q4 FY25 · Q3 FY25 · Q2 FY25 · Q1 FY25 · Q4 FY24
All COR earnings · Back to COR overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.